The human integrator complex is required for herpes simplex virus type 1 infection

Active Project Grant Awarded Last action

Award ID
F31AI202950
Recipient
Awarding agency
Obligated
$50,114

Award facts

Assistance listing
93.855 Allergy and Infectious Diseases Research
Completion date 0% complete
Place of performance
Rochester, NY 14611, USA

Award details come from USAspending.gov.

Description

As the agency reported it.

Abstract
Herpes simplex virus type 1 (HSV-1) is a widespread, double-stranded DNA alpha herpesvirus best known for its capacity to establish lifelong latency within neurons. Although many infected individuals experience no symptoms or only recurrent oral lesions, HSV-1 remains the primary cause of fatal viral encephalitis and is a major contributor to infectious blindness. Despite its substantial global burden, no licensed vaccine against HSV- 1 exists and antiviral agents such as acyclovir provide only limited benefit unless administered early in the lytic phase. HSV-1 depends entirely on host RNA polymerase II (rnapii) to drive viral gene expression, yet the molecular mechanisms that coordinate interactions between viral factors and host transcriptional regulators remain poorly defined. This proposal seeks to close this critical GAP by examining how the host rnapii regulatory apparatus is modulated during HSV-1 infection. The integrator complex (INT) is a multi-subunit, modular assembly that engages paused rnapii and facilitates promoter-proximal transcription termination. In doing so, INT suppresses expression of protein-coding genes and governs 3′-end processing of short noncoding transcripts, including enhancer rnas (ernas). Work from the wagner laboratory and others has demonstrated that INT carries out rnapii termination via two separable enzymatic functions: an RNA endonuclease activity residing in integrator subunit 11 (INTS11) and a phosphatase activity mediated by protein phosphatase 2A (PP2A), which directly associates with INTS8. Although INT is established as a central regulator of rnapii dynamics, its contribution to HSV-1 infection remains largely unexplored. To probe this question, we generated an auxin-inducible degron (aid) system that enables rapid (

Quick answers

Who received award F31AI202950?

F31AI202950 was awarded to University Of Rochester by National Institute of Allergy and Infectious Diseases (National Institutes of Health) on February 12, 2027.

How much is award F31AI202950 worth?

$50,114 has been obligated on F31AI202950.

On GovTribe

See this award's full record

  • Every transaction and subaward
  • The recipient's other awards and teaming partners
  • Similar grant awards
  • Ask GovTribe AI about this award
Try for free Login